Business
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001.
About this update from Betterlife Pharma Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, BetterLife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.","length":767,"tagName":"p"},{"type":"text","content":"Dr. Ahmad Doroudian, CEO of BetterLife, commented, "We are excited to work with the YAFO team to establish partnerships for the development of BETR-001 and to bring potential non-hallucinogenic treatments for neurological disorders to the Asian region. In recent years, YAFO has successfully concluded dozens of pharma and biotech cross-border transactions."","length":368,"tagName":"p"},{"type":"text","content":"Sean Jiang, Founder and CEO of YAFO, added, "We are pleased to partner with BetterLife Pharma on the advancement of BETR-001 into the Greater China region. The non-hallucinogenic profile of BETR-001 represents a highly differentiated approach in neurological therapeutics, with significant clinical and commercial potential. Through this collaboration, YAFO will leverage its deep expertise and strong pharmaceutical network to accelerate strategic partnering and development opportunities for BetterLife in Asia."","length":524,"tagName":"p"},{"type":"text","content":"BETR-001, a potent neuroplastogen, is BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, post-traumatic stress disorder and cluster headache. Previous forms of 2-bromo-LSD has been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (Karst et al, Cephalgia 2010).","length":477,"tagName":"p"},{"type":"text","content":"About YAFO...